European Institute of Oncology (IEO), Milano | Italy
EMBO 2006 | YipC 11–14
We study disease mechanisms and therapeutic opportunities in MYC-driven cancers. These tumors show 'oncogene addiction', implying that MYC itself – and presumably a subset of its target genes – are required for tumor maintenance. Moreover, the fitness of MYC-overexpressing cells depends on a fragile equilibrium between conflicting stress signals, providing opportunities to exploit synthetic lethality as a strategy for therapeutic intervention.
Keywords: Oncogenes / Myc / chromatin / transcription / cancer / lymphoma / therapy